E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: 20 September 2019

Special Issue Editor

Guest Editor
Prof. Marc Schmitz

Institute of Immunology, Medical Faculty Carl Gustav Carus, TU Dresden and Immune Monitoring Unit, National Center for Tumor Diseases Dresden, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstra├če 74, 01307 Dresden, Germany
Website | E-Mail
Interests: tumor immunology; tumor immunotherapy; tumor microenvironment; immune monitoring; dendritic cells; T cells; natural killer cells; tumor-associated antigens

Special Issue Information

Dear Colleagues,

In recent years, the immunotherapy of tumors has gained much momentum due to the development of novel attractive treatment modalities. One of these promising strategies is based on the inhibition of the immune checkpoint molecules programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1). The administration of antibodies targeting the PD-1/PD-L1 axis can induce objective clinical responses and improve survival in patients with various tumor types, including melanoma, non-small-cell lung cancer, and renal cell cancer. Based on their therapeutic efficiency, several antibodies have been approved for the treatment of tumor patients. However, many patients do not respond to anti-PD1/PD-L1 therapy. Therefore, the identification of biomarkers by using various immune monitoring technologies is required to select patients responding to treatment and to identify potential modes of treatment resistance. In addition, immune monitoring can lead to the discovery of novel mechanisms underlying the antitumor effects mediated by anti-PD1/PD-L1 therapy. In this context, the Special Issue will focus on the clinical outcomes of recent anti-PD1/PD-L1-based trials and the identification of novel biomarkers, which may foster the design of optimized treatment modalities for tumor patients.

Prof. Marc Schmitz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • tumor immunotherapy
  • check point inhibitors
  • programmed cell death protein 1
  • programmed cell death 1 ligand 1
  • biomarker
  • immune monitoring
  • T cells

Published Papers

This special issue is now open for submission.
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top